Comparative Pharmacology
Head-to-head clinical analysis: HEDULIN versus LIQUAEMIN LOCK FLUSH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEDULIN versus LIQUAEMIN LOCK FLUSH.
HEDULIN vs LIQUAEMIN LOCK FLUSH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEDULIN (phenindione) is an anticoagulant that inhibits vitamin K-dependent synthesis of coagulation factors II, VII, IX, and X in the liver, thereby reducing thrombus formation.
Heparin potentiates the activity of antithrombin III, thereby inactivating thrombin (factor IIa) and activated factor X (Xa), and preventing fibrin clot formation. It also inhibits factors IXa, XIa, and XIIa.
Oral, 200-400 mg initially, then 100-200 mg every 6-12 hours; maximum daily dose 1200 mg.
10-100 units/mL solution; flush intermittent intravenous catheters after each use with 1-5 mL; for central venous catheters, use 2-3 mL of 10 units/mL solution; for peripheral catheters, use 1-2 mL of 10 units/mL solution.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in patients with normal renal function; may be prolonged to 30-40 hours in renal impairment, necessitating dose adjustment.
1-2 hours (dose-dependent; prolonged with higher doses, renal impairment, or in elderly).
Renal excretion of unchanged drug accounts for approximately 70% of elimination; the remainder is metabolized hepatically and excreted in feces via bile.
Renal (predominantly via reticuloendothelial system and liver metabolism; unchanged drug excreted in urine).
Category C
Category C
Anticoagulant
Anticoagulant